(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number
WO 2005/007699 A3

(51) International Patent Classification[7]: C07K 16/24, A61K 39/395, C12N 15/13, A61P 11/06, 35/00

(21) International Application Number: PCT/GB2004/003059

(22) International Filing Date: 15 July 2004 (15.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/487,512	15 July 2003 (15.07.2003)	US
60/558,216	31 March 2004 (31.03.2004)	US
0407315.1	31 March 2004 (31.03.2004)	GB
60/573,791	24 May 2004 (24.05.2004)	US

(71) Applicant *(for all designated States except US)*: **CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge, Cambridgeshire CB1 6GH (GB).

(71) Applicants *(for US only)*: **JERMUTUS, Lutz** [DE/GB]; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED, Milstein Building, Granta Park, Cambridge, Cambridgeshire CB1 6GH (GB). **MINTER, Ralph, Raymond** [GB/GB]; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED, Milstein Building, Granta Park, Cambridge, Cambridgeshire CB1 6GH (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MONK, Phillip, David** [GB/GB]; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED, Milstein Building, Granta Park, Cambridge, Cambridgeshire CB1 6GH (GB). **SHORROCK, Celia, Patricia** [GB/GB]; CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED, Milstein Building, Granta Park, Cambridge, Cambridgeshire CB1 6GH (GB).

(74) Agents: **WALTON, Sean** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report: 12 May 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN ANTIBODY MOLECULES FOR IL-13

(57) Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

WO 2005/007699 A3